Crude Peptide Purification Optimization For Scalable Manufacturing

Once lentiviral vector goes straight into patients, it stops being an intermediate and becomes the final drug product, so impurity clearance and potency now carry drug-product requirements. T

raditional resin-based ion exchange often recovers only ~15–30% of the vector, which makes higher-dose systemic delivery hard to support. This brochure presents a membrane-based capture step that skips the low-salt wash and relies on convective flow, with total recovery rising from ~20% to ≥70% and about 98% host cell protein clearance. The process runs from a 1–2-day downstream workflow, and the platform has been scaled from bench to 500 L. Assays for titer, residual impurities, and safety support each stage.

Review the recovery and clearance data to see how the numbers compare.